Structure Therapeutics Inc. Financing Cash Flow
Structure Therapeutics Inc. (GPCR) reported Financing Cash Flow of $343.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-06
- Structure Therapeutics Inc. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $2.08M, a 303.29% increase year-over-year.
- Structure Therapeutics Inc. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was -$1.74M, a 315.33% decline year-over-year.
- Structure Therapeutics Inc. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $704.99M, a 114532.03% increase year-over-year.
- Structure Therapeutics Inc. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $56.20M.
- Structure Therapeutics Inc. net cash provided by (used in) financing activities for fiscal 2025 was $762.52M, a 47.99% increase from fiscal 2024.
- Structure Therapeutics Inc. net cash provided by (used in) financing activities for fiscal 2024 was $515.26M, a 14.11% increase from fiscal 2023.
- Structure Therapeutics Inc. net cash provided by (used in) financing activities for fiscal 2023 was $451.53M, a 1456.25% increase from fiscal 2022.
- Structure Therapeutics Inc. net cash provided by (used in) financing activities for fiscal 2022 was $29.01M.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.08M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $343.00K 10-Q · filed 2026-08-06 | $705.33M derived: sum of 3 quarters · filed 2026-08-06 | $761.53M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$1.74M 10-Q · filed 2026-05-07 | $703.25M derived: sum of 2 quarters · filed 2026-05-07 | $759.45M derived: sum of 3 quarters · filed 2026-05-07 | $759.97M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $704.99M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $761.19M derived: sum of 2 quarters · filed 2026-02-26 | $761.71M derived: sum of 3 quarters · filed 2026-08-06 | $762.52M 10-K · filed 2026-02-26 |
| 2025-09-30 | $56.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $56.72M derived: sum of 2 quarters · filed 2026-08-06 | $57.53M 10-Q · filed 2025-11-06 | $58.14M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $517.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $1.33M 10-Q · filed 2026-08-06 | $1.94M derived: sum of 3 quarters · filed 2026-08-06 | $1.18M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $809.00K 10-Q · filed 2026-05-07 | $1.42M derived: sum of 2 quarters · filed 2026-05-07 | $667.00K derived: sum of 3 quarters · filed 2026-05-07 | $515.37M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $615.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$142.00K derived: sum of 2 quarters · filed 2026-02-26 | $514.56M derived: sum of 3 quarters · filed 2026-02-26 | $515.26M 10-K · filed 2026-02-26 |
| 2024-09-30 | -$757.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $513.95M derived: sum of 2 quarters · filed 2025-11-06 | $514.65M 10-Q · filed 2025-11-06 | $796.28M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $514.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $515.40M 10-Q · filed 2025-08-06 | $797.03M derived: sum of 3 quarters · filed 2026-02-26 | $797.51M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $702.00K 10-Q · filed 2025-05-08 | $282.33M derived: sum of 2 quarters · filed 2026-02-26 | $282.80M derived: sum of 3 quarters · filed 2026-02-26 | $282.51M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $281.63M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $282.10M derived: sum of 2 quarters · filed 2026-02-26 | $281.81M derived: sum of 3 quarters · filed 2026-02-26 | $451.53M 10-K · filed 2026-02-26 |
| 2023-09-30 | $473.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $176.00K derived: sum of 2 quarters · filed 2024-11-13 | $169.90M 10-Q · filed 2024-11-13 | $169.59M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | -$297.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $169.43M 10-Q · filed 2024-08-08 | $169.11M derived: sum of 3 quarters · filed 2024-08-08 | $168.85M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $169.73M 10-Q · filed 2024-05-09 | $169.41M derived: sum of 2 quarters · filed 2024-05-09 | $169.15M derived: sum of 3 quarters · filed 2024-05-09 | $200.19M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | -$316.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-08 | -$575.00K derived: sum of 2 quarters · filed 2024-03-08 | $30.46M derived: sum of 3 quarters · filed 2024-03-08 | $29.01M 10-K · filed 2024-03-08 |
| 2022-09-30 | -$259.00K derived: 10-Q 9 month − 10-Q/A 6 month · filed 2023-11-17 | $30.78M derived: sum of 2 quarters · filed 2023-11-17 | $29.33M 10-Q · filed 2023-11-17 | |
| 2022-06-30 | $31.04M derived: 10-Q/A 6 month − 10-Q 3 month · filed 2023-11-17 | $29.59M 10-Q/A · filed 2023-11-17 | ||
| 2022-03-31 | -$1.45M 10-Q · filed 2023-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |